WO2020149393A1 - Procédé de sélection de substances améliorant l'odeur des matières fécales, procédé de fabrication de composition améliorant l'odeur des matières fécales, agent améliorant la fonction rénale, et boisson ou aliment destiné à améliorer la fonction rénale - Google Patents

Procédé de sélection de substances améliorant l'odeur des matières fécales, procédé de fabrication de composition améliorant l'odeur des matières fécales, agent améliorant la fonction rénale, et boisson ou aliment destiné à améliorer la fonction rénale Download PDF

Info

Publication number
WO2020149393A1
WO2020149393A1 PCT/JP2020/001430 JP2020001430W WO2020149393A1 WO 2020149393 A1 WO2020149393 A1 WO 2020149393A1 JP 2020001430 W JP2020001430 W JP 2020001430W WO 2020149393 A1 WO2020149393 A1 WO 2020149393A1
Authority
WO
WIPO (PCT)
Prior art keywords
salacia
renal function
improving
plant
extract
Prior art date
Application number
PCT/JP2020/001430
Other languages
English (en)
Japanese (ja)
Inventor
由里子 小田
文教 植田
忍 関
Original Assignee
富士フイルム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富士フイルム株式会社 filed Critical 富士フイルム株式会社
Priority to JP2020566495A priority Critical patent/JPWO2020149393A1/ja
Publication of WO2020149393A1 publication Critical patent/WO2020149393A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Definitions

  • the present invention relates to a method for selecting a substance that improves stool odor using blood urea nitrogen concentration as an index.
  • the present invention relates to a method for producing a composition for improving stool odor, which comprises the method described above.
  • the present invention further relates to a renal function improving agent, and a food or drink for improving renal function.
  • Roots and trunks of Salacia plants have been used as natural drugs in Ayurveda, a traditional medicine in India and Sri Lanka.
  • the root bark of Salacia reticulata is said to be effective in the treatment of rheumatism, gonorrhea and skin diseases, and the use of the root bark for the treatment of early stage diabetes.
  • Patent Document 1 describes a stool characterized by containing an extract or finely pulverized product of Kotara Himbutu (Salacia reticulate, Salacia oblonga), lactic acid bacteria and/or bifidobacteria, and indigestible oligosaccharides.
  • a sex improving agent is described.
  • Patent Document 2 discloses a reducing agent for enteric harmful bacteria containing hot water extract of Salacia plant, extract of green tea, and oolong tea powder, wherein the enteric harmful bacteria to be reduced are Enterobacter spp.
  • An agent for reducing intestinal harmful bacteria belonging to the genus Clostridium is described.
  • Patent Documents 1 and 2 describe that a predetermined composition containing an extract of a plant of the genus Salacia improves the intestinal environment, but it does not improve the blood urea nitrogen concentration and the fecal odor. The relationship was unknown.
  • the present inventors have found that human nitrogen ingested with an extract of a plant of the genus Salacia reduces blood urea nitrogen and improves stool odor. Furthermore, the present inventors confirmed suppression of proteolysis and amino acid biosynthesis, and promotion of peptide absorption in the functional analysis of intestinal bacteria in humans ingested with an extract of a plant of the genus Salacia. The present invention has been completed based on these findings. According to the present invention, the following inventions are provided.
  • a blood urea nitrogen concentration in a living body to which a test substance has been administered is compared with a blood urea nitrogen concentration in a living body to which a test substance has not been administered.
  • a method for selecting a substance that improves stool odor comprising the step of selecting, as a candidate substance, a test substance that is lower than the blood urea nitrogen concentration in a living body to which the test substance has not been administered.
  • the test substance is a pulverized product or extract of a plant of the genus Salacia.
  • a method for producing a composition for improving stool odor comprising: [6] The method according to [5], wherein the selected substance contained in the composition is a ground product or an extract of a Salacia plant. [7] The method according to [6], wherein the plant of the genus Salacia is at least one plant selected from Salacia reticulata, Salacia oblonga, and Salacia chinensis. .. [8] The method according to [6] or [7], wherein the ground product or extract of Salacia plant has a sucrase 50% inhibitory concentration of 1 to 1000 ⁇ g/mL.
  • a renal function improving agent containing a pulverized product or extract of a plant of the genus Salacia [12] The kidney according to [11], wherein the plant of the genus Salacia is at least one plant selected from Salacia reticulata, Salacia oblonga, and Salacia chinensis. Function improver. [13] The renal function-improving agent according to [11] or [12], wherein the crushed product or extract of a Salacia plant has a sucrase 50% inhibitory concentration of 1 to 1000 ⁇ g/mL. [14] The renal function improving agent according to any one of [11] to [13], which improves renal function by decreasing blood urea nitrogen concentration. [15] A food or drink for improving renal function, comprising the renal function improving agent according to any one of [11] to [14].
  • a method for improving renal function which comprises administering a pulverized product or extract of a Salacia plant to a subject in need of improved renal function.
  • a ground product or extract of a Salacia plant for use in a treatment for improving renal function.
  • a pulverized product or extract of a Salacia plant for the manufacture of a renal function improving agent. Further, according to the present invention, there is provided use of a pulverized product or extract of a Salacia plant for producing a food or drink for improving renal function.
  • a substance that can suppress the production of odorous substances can be obtained.
  • the method for producing a composition for improving stool odor according to the present invention it is possible to produce a composition for suppressing stool odor, which can suppress the production of odorous substances themselves.
  • renal function improving agent and the food and drink for improving renal function according to the present invention renal function can be improved by lowering the urea nitrogen concentration in blood.
  • Embodiments of the present invention will be described below.
  • Patent Documents 1 and 2 it has been known that a predetermined composition containing an extract of a Salacia plant improves the intestinal environment, but an extract of a Salacia plant contains blood urea nitrogen. It was unknown to reduce the concentration and to improve the stool odor with the decrease of blood urea nitrogen concentration.
  • the present invention suggests that the extract of a plant of the genus Salacia increases intestinal bacteria involved in the decomposition of proteins, promotes the decomposition of proteins into amino acids, and improves the uptake of amino acids into the body. ..
  • the measurement of stool odor generally requires labor and cost
  • the measurement of urea nitrogen is one of the items for health examination and has an advantage that it can be easily performed.
  • the composition produced by the present invention it is possible to improve the QOL (Quality of Life) of the care giver and the care receiver at the care site.
  • improving the post-toilet odor of women with constipation will reduce the mental burden.
  • the stool odor causes body odor, it is possible to improve body odor.
  • the method of selecting a substance that improves stool odor according to the present invention is a method of comparing the blood urea nitrogen concentration in a living body to which a test substance has been administered with the blood urea nitrogen concentration in a living body to which the test substance has not been administered.
  • the step of selecting a test substance as a candidate substance in the case where the blood urea nitrogen concentration in the living body to which is administered is lower than the blood urea nitrogen concentration in the living body to which the test substance is not administered is included.
  • the test substance is not particularly limited as long as it is a candidate substance that improves stool odor, and examples thereof include pulverized products or extracts of plants, animal tissue extracts, organic compounds (including synthetic low molecular weight compounds), proteins, peptides, Examples include microbial cultures and cell extracts, and these substances may be novel or known.
  • a crushed product or extract of a plant is preferable, and a crushed product or extract of a plant of the genus Salacia is particularly preferable. Details of the ground product or extract of Salacia will be described later.
  • the test substance may be administered to a living body as it is, or may be dissolved in a solvent as necessary and administered.
  • the living body to which the test substance is administered is not particularly limited, and may be a human or a mammal other than human (a rodent such as a mouse or a rat, a perissodactyla such as a horse or a donkey, a cow, a pig, a camel, a donkey, a goat). Or even cloven-hoofs such as sheep, pets such as dogs, cats or rabbits).
  • the number of administrations of the test substance is not particularly limited, but it can be administered once a day for 1 day to 2 months (for example, 4 weeks).
  • the blood urea nitrogen concentration in the living body can be measured by a conventional method known to those skilled in the art.
  • the blood urea nitrogen concentration is specifically measured by the urease method (a method in which urease is reacted with urea to form ammonia carbonate and the ammonia is measured), or a diacetyl monooxime method (urea in an acidic solution is mixed with diacetyl monoamine).
  • the method of comparing the color of oxime with orange-yellow) can be performed.
  • the urease method and the diacetylmonoxime method can utilize an automatic analysis method.
  • a test substance is selected as a candidate substance when the blood urea nitrogen concentration in the living body to which the test substance has been administered is lower than the blood urea nitrogen concentration in the living body to which the test substance has not been administered.
  • the first and second examples of "when the blood urea nitrogen concentration in the living body to which the test substance is administered are lower than the blood urea nitrogen concentration in the living body to which the test substance is not administered" are described below.
  • the first example is to administer a predetermined amount of a test substance to a living body for a predetermined period of time, measuring the blood urea nitrogen concentration before administration and the blood urea nitrogen concentration after administration, and measuring the blood concentration after administration.
  • the middle urea nitrogen concentration is lower than the blood urea nitrogen concentration before administration.
  • the blood urea nitrogen concentration after administration is lower than the blood urea nitrogen concentration before administration by 0.1 mg/dL or more, or there is a 5% significant difference when comparing before and after administration.
  • the blood urea nitrogen concentration after administration is 0.2 mg/dL or lower, 0.3 mg/dL or lower, 0.4 mg/dL or lower, or 0. It may be lower by 5 mg/dL or more.
  • a living body to which a predetermined amount of test substance is administered for a predetermined period and a living body to which a control not containing the test substance is administered are prepared.
  • the blood urea nitrogen concentration before administration and the blood urea nitrogen concentration after administration are measured, and the change amount (reduction amount) of the blood urea nitrogen concentration before and after administration is determined.
  • the second example is that the amount of change (decrease) in blood urea nitrogen concentration before and after administration in the living body to which the test substance was administered is This is the case when it is larger than the change amount (reduction amount).
  • the change (decrease) in blood urea nitrogen concentration before and after administration in a living body to which a test substance was administered is smaller than the change (decrease) in blood urea nitrogen concentration before and after administration in a living body to which a test substance-free control was administered. , 0.1 mg/dL or more, or a 5% significant difference when performing intergroup comparison.
  • the change (decrease) in blood urea nitrogen concentration before and after administration in a living body to which the test substance is administered is smaller than the change (decrease) in blood urea nitrogen concentration before and after administration in a living body to which a test substance-free control is administered.
  • 0.2 mg/dL or more low 0.3 mg/dL or more low, 0.4 mg/dL or more low, 0.5 mg/dL or more low, 1.0 mg/dL or more low, 1.5 mg/dL or more low, Alternatively, it may be lower than 2.0 mg/dL.
  • the plant of the genus Salacia is a plant of the family Dechinmuru that grows mainly in Sri Lanka, India, and Southeast Asia, and more specifically, Salacia reticulata, Salacia oblonga, and Salacia prinoides.
  • Salacia chinensis Salacia latifolia, Salacia brununiana, Salacia grandiflora (Salacia grandifacler) and Salacia grandiflora (Salacia grandiflora) and Salacia sperma Plants.
  • the plant of the genus Salacia is preferably at least one plant selected from Salacia reticulata, Salacia oblonga, and Salacia chinensis.
  • a pulverized product or extract of a Salacia plant means a pulverized product or extract of an edible part such as a root, a trunk, a leaf, a flower or a fruit of a Salacia plant, a dried product of the pulverized product or extract.
  • the dried product may be a dry powder (extract powder).
  • extract powder obtained by drying the extract extracted from the site selected from the root and the trunk is used.
  • the dry powder can be preferably obtained by extracting the edible part of a Salacia plant with a solvent and drying the extract obtained above.
  • the solvent used for extraction include water, alcohol, and ketone, and a mixed solvent obtained by mixing two or more of these may be used.
  • alcohols include methanol and ethanol, with ethanol being preferred.
  • ketone acetone, methyl ethyl ketone, cyclohexane or the like is preferable.
  • water, alcohol, a mixed solvent of water and alcohol, or a mixed solvent of water and ketone is preferable, water, alcohol, or a mixed solvent of water and alcohol is more preferable, and heat of 50° C. to 98° C. Water, ethanol, or a mixed solvent of water and ethanol is more preferable.
  • the alcohol content in the mixed solvent of water and alcohol is preferably 30% by mass to 90% by mass, more preferably 40% by mass to 70% by mass.
  • the drying method for drying the extract to obtain a dry powder is not particularly limited, and known drying methods such as spray drying and freeze drying can be used. It is also possible to prepare a dry powder by using a known excipient, for example, a sugar such as dextrin. From the viewpoint of obtaining a more active dry powder, it is preferable to prepare the extract as it is by spray drying such as spray drying.
  • ⁇ -glucosidase inhibitory activity The crushed product or extract of the plant of the genus Salacia may have ⁇ -glucosidase inhibitory activity or may not have ⁇ -glucosidase inhibitory activity.
  • sucrase 50% inhibitory concentration (IC 50 value) as an index of ⁇ -glucosidase inhibitory activity can be measured by the following method.
  • Measurement of sucrase IC 50 value Preparation of sample solution: Weigh 2 mg of sample into a tube, add 2 mL of water, and suspend well to prepare a sample solution of 1 mg/mL concentration. This is diluted with water to 0, 50, 100, 250 and 500 ⁇ g/mL, respectively.
  • Preparation of substrate solution Sucrose is dissolved in a 0.2 mol/L maleic acid buffer (pH 6.0) to a sucrose concentration of 100 mmol/L, and this is used as a substrate solution.
  • Preparation of crude enzyme solution After suspending 1 g of intestinal acetate powder rat (manufactured by SIGMA) in 10 mL of physiological saline, centrifugation (3,000 rpm, 4° C., 5 minutes) is performed. The obtained supernatant is separated and used as a crude enzyme solution.
  • Preparation of blank To 250 ⁇ L of the sample solution of each concentration described above, 200 ⁇ L of substrate solution and 50 ⁇ L of crude enzyme solution were added, and immediately heated at 95° C. for 2 minutes to inactivate the enzyme to obtain blank data. .. A calibration curve is prepared from the obtained values and the concentration at which enzyme activity is inhibited by 50% (IC 50 value) is determined.
  • the sucrose 50% inhibitory concentration (IC 50 value) of the pulverized product or extract of Salacia plant used in the present invention is preferably 1 to 1000 ⁇ g/mL, more preferably 1 to 800 ⁇ g/mL, and further preferably It is 1 to 600 ⁇ g/mL, and more preferably 1 to 400 ⁇ g/mL.
  • the method for producing a composition for improving stool odor according to the present invention includes the steps of selecting a substance for improving stool odor according to the method of the present invention described above; and mixing the selected substance with a carrier.
  • ingestion of a composition that improves stool odor can exhibit increased digestion and absorption of proteins and decreased biosynthesis of phenylalanine, tyrosine and tryptophan in the intestine.
  • the present invention further relates to a renal function improving agent, which comprises a pulverized product or extract of a Salacia plant.
  • the present invention further provides a method for improving renal function, which comprises administering a pulverized product or extract of a Salacia plant to a subject in need of improved renal function.
  • the ground product or extract of the plant of the genus Salacia is as described above in the present specification.
  • the renal function improving agent of the present invention is preferably capable of improving renal function through a decrease in blood urea nitrogen concentration.
  • various carriers which are pharmaceutically or food hygienically acceptable, for example, an excipient, a lubricant, a stabilizer, a dispersant, a binder. It can be prepared by using one or more additives selected from agents, diluents, flavors, sweeteners, flavors, and coloring agents, and preferably it can be prepared as an oral administration agent.
  • composition for improving stool odor and the renal function improving agent may further contain other components in addition to the substance for improving stool odor selected by the method of the present invention.
  • other components include, but are not particularly limited to, lactic acid bacteria, mineral yeast, flavonoids, polyphenols, and oral substances having an immunostimulating action.
  • Specific examples of the other components include the components described in paragraph Nos. 0023 to 0038 of JP-A-2015-127340.
  • composition for improving stool odor and the renal function improving agent further include vitamins, vitamin-like substances, proteins, amino acids, oils and fats, organic acids, carbohydrates, plant-derived raw materials, animal-derived raw materials, microorganisms, food additives, and Orally ingestible components such as one or more selected from pharmaceutical additives can be appropriately contained.
  • composition of the composition for improving stool odor and the form of the renal function improving agent are not particularly limited as long as they exhibit the effects of the present invention, and examples thereof include tablets, pills, granules, fine granules, chewing agents, and capsules. It may be in the form of an agent (filled in a hard capsule or a soft capsule), a liquid agent, a chewable agent, or a food or drink as described below.
  • the dosage forms described above can be prepared using conventional methods known to those skilled in the art.
  • pills and granules they may be in the form of conventional coatings, if necessary, such as sugar-coated tablets, gelatin encapsulating agents, enteric encapsulating agents, film coating agents, and the like.
  • the tablets may be multilayer tablets such as double tablets.
  • a composition for improving stool odor containing a pulverized product or an extract of a Salacia plant, and a renal function improving agent improve calcium carbonate and a desiccating agent in order to improve discoloration of the pulverized product or extract of a Salacia plant over time. It is preferred to incorporate silicon dioxide (preferably finely divided silicon dioxide).
  • the composition for improving stool odor and the renal function improving agent are tablets or capsules
  • the addition of calcium carbonate or silicon dioxide each may be contained alone by 1% by mass or more, and the total of calcium carbonate and silicon dioxide may be contained by 1% by mass or more.
  • the upper limit of the addition amount of calcium carbonate is 2.5% by mass and the upper limit of the addition amount of silicon dioxide is 2.0% by mass according to the Food Sanitation Law, which improves stool odor.
  • the added amount of calcium carbonate is 2.5% by mass or less and the added amount of silicon dioxide is 2.0% by mass or less.
  • the composition for improving stool odor and the renal function improving agent can be mixed with a low hygroscopic material, a hygroscopic agent, an antioxidant, etc., which can be used as a food or a food additive.
  • a low hygroscopic material a hygroscopic agent, an antioxidant, etc.
  • Cellulose, crystalline cellulose, powdered cellulose, microcrystalline cellulose, lactose, oligosaccharide, sugar alcohol, trehalose, magnesium stearate, calcium stearate, sucrose fatty acid ester and the like are preferably used as the low hygroscopic material.
  • silicates, magnesium carbonate, ferrocyanide, polysaccharides and the like are used.
  • crystalline cellulose, microcrystalline cellulose, lactose or sucrose fatty acid ester is used as the low hygroscopic material.
  • As the antioxidant ascorbic acid, sodium ascorbate or the like is used.
  • composition for improving stool odor and the renal function-improving agent may further appropriately contain a compound necessary for molding into a powder, a solid agent or a liquid agent.
  • a compound necessary for molding into a powder, a solid agent or a liquid agent examples include erythritol, maltitol, hydroxypropyl cellulose, kaolin, talc and the like.
  • composition for improving stool odor and method of using renal function-improving agent Composition for improving stool odor and method of using renal function-improving agent
  • the composition for improving stool odor and the renal function-improving agent can be orally administered to mammals including humans.
  • the daily intake or dose of the crushed product or extract of a Salacia plant Is preferably 0.1 mg/kg/day or more, more preferably 0.5 mg/kg/day or more, further preferably 1.0 mg/kg/day or more, further preferably 2.0 mg/kg/day or more, 4 It is more preferably 0.0 mg/kg/day or more.
  • the upper limit of the daily intake or dose of the pulverized product or extract of Salacia plant is not particularly limited, but it is generally 100 mg/kg/day or less, and preferably 50 mg/kg/day or less.
  • the amount of the ground substance or extract of Salacia plant contained in the composition for improving stool odor and the renal function improving agent can be set appropriately.
  • each tablet contains 1/3 of the daily intake.
  • the renal function improving agent of the present invention can be administered to a subject in need of renal function improvement.
  • Subjects requiring improvement in renal function include acute glomerulonephritis, minimal change nephritis, chronic glomerulonephritis, nephrosclerosis, membranous proliferative nephritis, mesangial proliferative glomerulonephritis, membranous proliferative glomerulonephritis.
  • Renal failure such as chronic renal failure, amyloid kidney, membranous nephropathy, focal glomerulosclerosis, IgA nephropathy, acute tubular necrosis, nephrotic syndrome, diabetic nephropathy, gouty kidney, renal edema, Mention may be made of subjects suffering from diseases such as renal tumor, renal ischemic injury, renal ischemia-reperfusion injury.
  • the form of the renal function-improving agent of the present invention is not particularly limited, and may be, for example, any of foods and drinks (including beverages and supplements), food materials, quasi drugs, pharmaceuticals, pharmaceutical materials, and quasi drug materials. Good. That is, according to the present invention, there is provided a food or drink for improving renal function, which comprises the renal function improving agent of the present invention.
  • Examples of food and drink include health foods (tablets, granules, capsules, powders, etc.), drinks and beverages.
  • the form of the food or drink of the present invention is not particularly limited, and can be various forms that can be supplied to the body mainly by the oral route.
  • the food of the present invention can be provided in the form of, for example, powdered food, granular food, sheet food, bottled food, canned food, retort food, capsule food, tablet food, liquid food, or drink. ..
  • the food and drink of the present invention can be used as foods such as health foods, functional foods, dietary supplements and foods for specified health uses. In particular, it can be in the form of noodles, confectionery, rice and the like.
  • the food and drink of the present invention in the case of a functional food form, not only general foods such as nutritional drinks, nourishing tonics, palatable beverages, frozen desserts, but also tablets, granules, capsule-like dietary supplements. It is also preferable to provide
  • the food or drink of the present invention may optionally contain components generally used in foods, in addition to the renal function improving agent of the present invention.
  • components that can be used in the food or drink of the present invention for example, colorants, preservatives, thickening stabilizers, antioxidants, colorants, bleaches, fungicides, gum bases, bittering agents, enzymes, brighteners, Examples thereof include acidulants, seasonings, emulsifiers, reinforcing agents, manufacturing agents (excipients), flavors, spice extracts, pH adjusters and the like.
  • the pH of the food or drink of the present invention is preferably 8.0 or less, more preferably 7.0 or less, and further preferably 3.0 to 6.0.
  • the pH adjuster that can be used to adjust the pH of foods and drinks any one that is commonly used in the food field can be used.
  • Examples of the pH adjuster that can be used for foods and drinks include gluconic acid, L-tartaric acid, malic acid, lactic acid, adipic acid, succinic acid, acetic acid, fumaric acid, phytic acid and derivatives thereof, and baking soda.
  • gluconic acid L-tartaric acid
  • malic acid lactic acid, adipic acid
  • succinic acid acetic acid, fumaric acid, phytic acid and derivatives thereof
  • baking soda Gluconic acid
  • L-tartaric acid gluconic acid
  • malic acid lactic acid, adipic acid
  • succinic acid acetic acid
  • fumaric acid phytic acid and derivatives thereof
  • baking soda Gluconic acid
  • sodium carbonate sodium carbonate
  • sodium hydroxide calcium hydroxide
  • disodium hydrogen phosphate sodium dihydrogen phosphate
  • dipotassium hydrogen phosphate potassium dihydrogen phosphate
  • potassium carbonate and other inorganic acids.
  • ingredients that can be used in foods and drinks include milk protein, soy protein, egg albumin protein, etc., or egg white oligopeptides, soybean hydrolysates, and mixtures of amino acids, which are their degradation products.
  • the food and drink of the present invention is a processed product such as a natural liquid food containing sugars, fats, trace elements, vitamins, emulsifiers, flavors, etc. It can take the form of a thing.
  • nutritional additives such as amino acids, vitamins and minerals, sweeteners, spices, fragrances and pigments are used to improve nutritional balance and flavor when ingested. You may mix
  • the renal function improving agent of the present invention When used as a food or drink, its content can be appropriately selected according to the purpose.
  • the content of the pulverized product or extract of Salacia plant in the food or drink of the present invention is relative to the total amount of the food or drink, It is preferably in the range of 1% by mass to 60% by mass, and more preferably in the range of 1% by mass to 40% by mass.
  • a ground product or extract of a Salacia plant for use in a treatment for improving renal function. Further, according to the present invention, there is provided use of a pulverized product or extract of a Salacia plant for producing a renal function improving agent or a food or drink for improving renal function.
  • a pulverized product or extract of a Salacia plant for producing a renal function improving agent or a food or drink for improving renal function.
  • Example 1 The roots and stems of S. reticulata and S. oblonga were crushed and mixed in equal weights, and the resulting solution was subjected to a hot water extraction step at 98° C. to be spray-dried. Salacia extract powder was obtained. The obtained Salacia extract powder was used to prepare tablets with the following formulation.
  • Example 2 Measurement of sucrase IC 50 value
  • sample solution A sample of 2 mg is weighed in a tube, and 2 mL of water is added and well suspended to prepare a sample solution having a concentration of 1 mg/mL. This is diluted with water to 0, 50, 100, 250 and 500 ⁇ g/mL, respectively.
  • substrate solution Sucrose is dissolved in a 0.2 mol/L maleic acid buffer (pH 6.0) to a sucrose concentration of 100 mmol/L, and this is used as a substrate solution.
  • the produced glucose concentration is quantified using a commercially available kit mutarotase glucose oxidase method (Glucose CII Test Wako, Fujifilm Wako Pure Chemical Industries, Ltd.).
  • Preparation of blank To 250 ⁇ L of the sample solution of each concentration described above, 200 ⁇ L of the substrate solution and 50 ⁇ L of the crude enzyme solution were added, and immediately heated at 95° C. for 2 minutes to inactivate the enzyme to obtain blank data. ..
  • the sucrase IC 50 value of the measured sample was 1 to 1000 ⁇ g/mL.
  • Example 3 Measurement of urea nitrogen in blood 30 adult males were randomly divided into 2 groups, a Salacia group and a placebo group.
  • the tablet containing the extract of the plant of the genus Salacia described in Example 1 and the tablet prepared only with the excipient were ingested for 1 week for 1 week for 4 weeks, and the urea nitrogen concentration in blood was measured by the urease method.
  • the amount of change in urea nitrogen (average value for 15 persons in each group) before ingestion of the tablets and after 4 weeks of ingestion of the tablets is shown below.
  • Example 4 Evaluation of stool odor 30 subjects of Example 3 (Salacia group: 15 persons, placebo group: 15 persons) were asked to answer the following questionnaire, and feces before and after the test described in Example 3 The odor change was evaluated. ⁇ Questionnaire items> 5 points: The odor of stools is very odorous. 4 points: The stool has a strong odor. 3 points: The stool smell is felt, but not. 2 points: The odor of stools is not so noticeable and I do not care much. 1 point: Almost no odor of stool was felt, and it did not bother me at all.
  • Example 5 Functionality of human intestinal bacteria
  • 1 g of the tablet containing the Salacia plant extract described in Example 1 as a test diet was ingested daily for 1 week for 2 weeks, and feces were collected.
  • the pretreatment of feces was performed according to 16S Metagenomic Sequencing Library Preparation provided by Illumina Co., Ltd., and sequence analysis was performed using Miseq (Illumina) based on the method provided by Illumina.
  • the obtained text data was analyzed using Quantitative Insights Into Microbiology Ecology (QIIME; Pycogent), and the data of the bacterial occupancy at the genus level was calculated.
  • QIIME Quantitative Insights Into Microbiology Ecology
  • a PICRUSt analysis for estimating the functionality of intestinal bacteria was carried out using the data, and an increase in “protein digestion and absorption” and a decrease in “Phenylalanine, tyrosine and tryptophan biosynthesis” were confirmed.
  • Example 6 Improvement of skin condition In a Salacia ingestion test (4 weeks) targeting 10 women in their 30s with constipation, 4% of them answered that their skin condition improved. It was Very bad: 0 people Bad: 1 person No change: 2 people Better: 4 people Very good: 3 people

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention a pour objet de fournir un procédé de sélection de substances améliorant l'odeur des matières fécales, et un procédé de fabrication de composition améliorant l'odeur des matières fécales. En outre, l'invention a pour objet de fournir un agent améliorant la fonction rénale, et une boisson ou aliment destiné à améliorer la fonction rénale. Plus précisément, l'invention fournit un procédé de sélection de substances améliorant l'odeur des matières fécales qui inclut une étape au cours de laquelle la concentration en azote uréique dans le sang dans un corps vivant auquel une substance test a été administrée, et la concentration en azote uréique dans le sang dans un corps vivant auquel la substance test n'a pas été administrée, sont comparées, et la concentration en azote uréique dans le sang dans un corps vivant auquel la substance test a été administrée, sélectionne en tant que substance candidate, la substance test dans le cas où elle présente une concentration plus basse en azote uréique dans le sang dans un corps vivant auquel la substance test n'a pas été administrée.
PCT/JP2020/001430 2019-01-18 2020-01-17 Procédé de sélection de substances améliorant l'odeur des matières fécales, procédé de fabrication de composition améliorant l'odeur des matières fécales, agent améliorant la fonction rénale, et boisson ou aliment destiné à améliorer la fonction rénale WO2020149393A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020566495A JPWO2020149393A1 (fr) 2019-01-18 2020-01-17

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019006646 2019-01-18
JP2019-006646 2019-01-18

Publications (1)

Publication Number Publication Date
WO2020149393A1 true WO2020149393A1 (fr) 2020-07-23

Family

ID=71614401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/001430 WO2020149393A1 (fr) 2019-01-18 2020-01-17 Procédé de sélection de substances améliorant l'odeur des matières fécales, procédé de fabrication de composition améliorant l'odeur des matières fécales, agent améliorant la fonction rénale, et boisson ou aliment destiné à améliorer la fonction rénale

Country Status (2)

Country Link
JP (1) JPWO2020149393A1 (fr)
WO (1) WO2020149393A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000239179A (ja) * 1999-02-17 2000-09-05 Kuressendo Corporation:Kk 運動時のアンモニア生成抑制による運動能力の向上
US6168803B1 (en) * 1993-10-14 2001-01-02 Westway Trading Corporation Process for preparing rigid animal feedblocks
JP2004285007A (ja) * 2003-03-24 2004-10-14 En Otsuka Pharmaceutical Co Ltd 消臭成分を含む栄養組成物
JP2007031345A (ja) * 2005-07-27 2007-02-08 Seiko:Kk 腸内環境改善作用を有する食品組成物
JP2009137899A (ja) * 2007-12-07 2009-06-25 Fujifilm Corp 腸内有害菌低減剤、それを含む食品または医薬品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168803B1 (en) * 1993-10-14 2001-01-02 Westway Trading Corporation Process for preparing rigid animal feedblocks
JP2000239179A (ja) * 1999-02-17 2000-09-05 Kuressendo Corporation:Kk 運動時のアンモニア生成抑制による運動能力の向上
JP2004285007A (ja) * 2003-03-24 2004-10-14 En Otsuka Pharmaceutical Co Ltd 消臭成分を含む栄養組成物
JP2007031345A (ja) * 2005-07-27 2007-02-08 Seiko:Kk 腸内環境改善作用を有する食品組成物
JP2009137899A (ja) * 2007-12-07 2009-06-25 Fujifilm Corp 腸内有害菌低減剤、それを含む食品または医薬品

Also Published As

Publication number Publication date
JPWO2020149393A1 (fr) 2020-07-23

Similar Documents

Publication Publication Date Title
JP6684966B2 (ja) 新規なラクトバチルス・サケイ及びそれを含む組成物
KR102153080B1 (ko) 신규한 락토바실러스 살리바리우스 hem 1047 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
EP2799083A1 (fr) Agent de prévention de l'atrophie musculaire
EP2271367B1 (fr) Accélérateur d'absorption de minéraux et agent ou composition alimentaire améliorant l'anémie ferriprive
JP6573639B2 (ja) 腸内細菌数抑制剤、食品、及び医薬品
KR20180122380A (ko) 피칼리박테리움속 세균증식제
JP5281895B2 (ja) カルシウム吸収促進剤
WO2020149393A1 (fr) Procédé de sélection de substances améliorant l'odeur des matières fécales, procédé de fabrication de composition améliorant l'odeur des matières fécales, agent améliorant la fonction rénale, et boisson ou aliment destiné à améliorer la fonction rénale
JPWO2018056284A1 (ja) 腸内菌叢改善用組成物
JP2008074734A (ja) インスリン抵抗性改善剤
KR102215592B1 (ko) 신규한 락토바실러스 퍼멘텀 hem 1036 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
WO2016133155A1 (fr) Inhibiteur d'alpha-glucosidase
US20080220052A1 (en) Body weight gain inhibitor
JP6131275B2 (ja) Ｉｇｆ−１産生促進剤
JPWO2009031603A1 (ja) 脂肪吸収抑制組成物
JP2010043036A (ja) 糖代謝促進剤
JP2008239521A (ja) アンジオテンシン変換酵素阻害剤およびその製造方法
JP6981641B2 (ja) Ｐｄｅ５活性阻害剤
TW201927326A (zh) 源自綠茶萃取物之發酵物的製造方法以及源自綠茶萃取物之麴發酵物、以及含有源自綠茶萃取物之麴發酵物的組成物
WO2021132453A1 (fr) Agent d'inhibition des troubles des vaisseaux sanguins capillaires, agent d'amélioration des troubles des vaisseaux sanguins capillaires, et agent d'accélération d'angiogenèse capillaire
KR102612548B1 (ko) 락토바실러스 부크너리 200793 균주를 포함하는 우울증예방, 개선 또는 치료용 조성물
KR102215594B1 (ko) 신규한 락토바실러스 람노서스 hem 648 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
WO2020203079A1 (fr) Agent de renforcement musculaire
JP2005239686A (ja) 脂肪燃焼促進組成物及び該組成物を含有する食品又は医薬品
KR20230153030A (ko) 신규한 비피도박테리움 비피덤 hem972 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20741889

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2020566495

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20741889

Country of ref document: EP

Kind code of ref document: A1